• OPEN AN ACCOUNT
Indian Indices
Sensex
79,116.19 -1,122.66
( -1.40%)
Global Indices
Nasdaq
48,521.56 -404.23
(-0.83%)
Dow Jones
6,836.74 -65.88
(-0.95%)
Hang Seng
54,115.64 -2,163.41
(-3.84%)
Nikkei 225
10,568.52 84.39
(0.80%)
Forex
USD-INR
91.48 0.43
(0.47%)
EUR-INR
107.28 -0.27
(-0.25%)
GBP-INR
122.62 -0.09
(-0.07%)
JPY-INR
0.58 0.00
(-0.14%)

EQUITY - MARKET SCREENER

Maruti Suzuki India Ltd
Industry :  Automobiles - Passenger Cars
BSE Code
ISIN Demat
Book Value()
532500
INE585B01010
3098.3429953
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MARUTI
31.14
452129.77
EPS(TTM)
Face Value()
Div & Yield %
461.82
5
0.94
 

delphi world money ltd
Aurobindo Pharma arm receives 4 observations after US FDA inspection
Feb 28,2026
The facility (Unit-I), located at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, was inspected from 16 February to 27 February 2026, and the inspection concluded with four observations. The company said it will respond to the US FDA within the stipulated timelines.

The company confirmed there is no impact on its financials or operations due to the inspection. Aurobindo Pharma stated its commitment to maintaining high-quality manufacturing standards across all its facilities worldwide and said it will update the stock exchanges if there is any further information.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company’s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.04% to end at Rs 1,221.55 on the BSE on Friday.